Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been ...

Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been ...

In a new survey, 56% of respondents said they plan to get a flu shot this fall, while just 43% said they'll get an updated ...

An ingredient in the hair dye a French woman used caused her to develop a vision-robbing retinopathy, researchers report.

Here are four big drug/biotech stocks, LLY, RHHBY, NVS and PFE, which you should buy today for lucrative long-term returns.

Demand for Eli Lilly’s Zepbound and Mounjaro has outstripped supply over the last year, forcing the company to invest heavily ...

Eli Lilly has again upped the ante in scaling up its manufacturing footprint, this time revealing an investment totaling $1.8 billion to expand production capacity at two plants in Ireland. | Eli ...

Compared to the placebo, patients treated with Kisunla had a 35% slower cognitive and functional decline at 18 months of ...

Pharmaceutical giant Eli Lilly (LLY) says it will spend $1.8 billion U.S. to expand its manufacturing capacity as it tries to ...

The next generation of Alzheimer’s therapeutics is moving away from amyloid plaques and tau tangles, offering multiple ...

Kisunla (donanemab-azbt) is a brand-name injection for IV infusion that’s prescribed for certain types of Alzheimer’s disease in adults. As with other drugs, Kisunla can cause side effects ...

A Hartsville hospital patient is among the first in the United States to receive a new treatment that helps slow the ...